Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.
Your donations power the high-quality news San Diego deserves. Help us reach our $10,000 goal by April 10.
Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat genetic neuromuscular diseases.